EUVIMEDEUVIMED entdecken
CrossrefInfokarte

Danhong Injection combined with t-PA attenuates cerebral ischemia/reperfusion injury and reduces hemorrhagic transformation: association with NF-κB/MMPs signaling

Jinghui Zhang, Chuchu Shan, Zebin Yu, Rui Shi, Changyi Ye, Bin Zhang, Yuyan Zhang, Shan Xu

Journal of Pharmacy and Pharmacology · 2026-10-01 · 78 (10)

DOI: 10.1093/jpp/rgag129 ↗
AbstractBibliografische Angaben

Abstract

Abstract Objectives Ischemic stroke, caused by cerebral arterial thrombosis and interrupted blood supply, is a leading cause of brain dysfunction. Tissue plasminogen activator (t-PA) is the standard thrombolytic agent but is limited by hemorrhagic transformation (HT) and blood–brain barrier (BBB) damage. This study explored the beneficial effects of Danhong Injection (DHI, a Traditional Chinese Medicine) as an adjuvant combined with t-PA for the treatment of ischemic stroke. Methods Based on cell viability assays, optimal concentrations were 20 μl/ml DHI + 20 μg/ml t-PA. In vitro (mouse brain microvascular endothelial cell, OGD/R model) and in vivo (MCAO rat model) experiments were conducted to assess relevant parameters. Key findings In vitro, the combination improved cell morphology, reduced apoptosis, and downregulated phosphorylated NF-κB p65, MMP-2, MMP-9, and hypoxia-inducible factor-1α expression. In vivo, DHI + t-PA decreased P-Selectin, 6-keto-PGF1a, TXA2, PAI-1, MMP-2, and MMP-9 levels, alleviated cerebral infarction and HT, and enhanced neurological recovery. Conclusions These protective effects were accompanied by downregulation of the NF-κB/MMPs pathway, suggesting a plausible correlation linked to BBB-related protective phenotypes. Our findings provide preliminary evidence supporting DHI as a promising adjuvant to optimize t-PA-based stroke therapy.

Wissen, das zu Ihrer Arbeit passt.

Vom kostenlosen Einstieg über die persönliche Recherche bis zur vollständigen Research Suite.

Tarife ansehen →

Sind alle Verlagsvolltexte enthalten?

Nein. Bibliografische Nachweise, Abstracts und Volltexte sind unterschiedliche Inhalte. Ob ein Volltext verfügbar ist, hängt von der Quelle, Open Access und Ihren vorhandenen Lizenzen ab. Ein EUVIMED-Tarif ersetzt keine zusätzlichen Verlagsrechte.

Tarife ansehen →